AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for oncology: Harnessing ubiquitin-independent pathways

Study ubiquitin-independent targeted protein degradation for oncology in Catherine Lindon’s laboratory, in partnership with AstraZeneca. The project investigates Midnolin biology and develops binding and engineered tools that redirect its activity towards therapeutic targets. The award supports four years of doctoral research.

Applicants should have or expect a first or high upper-second-class degree, or overseas equivalent, with appropriate biochemistry and cell-biology knowledge. Home-rate fees are funded. Overseas applicants must qualify for Home fees or secure separate scholarship funding for the fee difference; self-funding that difference is not permitted.